Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
18.55 USD | +1.09% | -4.43% | 0.00% |
Jun. 05 | ArriVent, Alphamab Unit to Collaborate on Antibody Drug Conjugates For Cancer Treatment | MT |
Jun. 05 | Alphamab Strikes Deal with Nasdaq-Listed ArriVent to Co-Develop Antibody Drug Conjugates | MT |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 621M |
---|---|---|---|---|---|
Net income 2024 * | -75M | Net income 2025 * | -92M | EV / Sales 2024 * | - |
Net cash position 2024 * | 201M | Net cash position 2025 * | 502M | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-6.39
x | P/E ratio 2025 * |
-5.98
x | Employees | 40 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 86.32% |
1 day | +1.09% | ||
1 week | -4.43% | ||
Current month | -4.43% | ||
1 month | +3.11% | ||
3 months | -5.41% |
Date | Price | Change | Volume |
---|---|---|---|
24-06-07 | 18.55 | +1.09% | 19,083 |
24-06-06 | 18.35 | -1.71% | 12,666 |
24-06-05 | 18.67 | +1.85% | 28,103 |
24-06-04 | 18.33 | -4.48% | 41,968 |
24-06-03 | 19.19 | -1.13% | 41,204 |
Delayed Quote Nasdaq, June 07, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
0.00% | 621M | |
+51.85% | 57.87B | |
+41.48% | 40.25B | |
-5.25% | 39.94B | |
-5.16% | 28.54B | |
+12.79% | 26.4B | |
-20.18% | 19.33B | |
+30.88% | 12.4B | |
+0.61% | 12.23B | |
+25.06% | 12.2B |
- Stock Market
- Equities
- AVBP Stock